PIK3CA and cancer: Indeed, dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 or rapalogs in combination with PI3K or AKT inhibitors has demonstrated profound efficacy in a variety of preclinical models of cancers [34-37, 50-56].